Possibilities of etiotropic and pathogenetic therapy of respiratory viral infections by means of enisamium iodide medicine


DOI: https://dx.doi.org/10.18565/therapy.2024.2.164-171

Cherenkova O.V., Goncharova N.Yu., Batishcheva G.A.

N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia
Abstract. Respiratory viral infections are characterized by high morbidity, more severe clinical course in comorbid patients, and the possibility of bacterial complications arising. Treatment strategy for influenza and acute respiratory viral infections (ARVI) includes the use of antiviral drugs and medications reducing the symptoms of viral intoxication. At the same time, drugs that simultaneously produce several pharmacological effects are of promising importance. Enisamium iodide medicine meets these requirements. It has been proven in experimental models that it suppresses the replication of respiratory viruses, enhances synthesis of endogenous alpha and gamma interferons, and has an anti-inflammatory and decongestant effect. In clinical studies, the administration of enisamium iodide for coronavirus infection, influenza and ARVI provided more rapid relief of symptoms and reduction of the incidence of complications. The drug is also distinguished by a favorable safety profile and the possibility of being prescribed for diseases of the gastrointestinal tract.
Keywords: enisamium iodide, interferons, influenza, acute respiratory viral infections, antiviral therapy
Read entire article

Literature

1. Викулов Г.Х. Новые и возвращающиеся вирусные инфекции: алгоритмы диагностики и терапии. РМЖ. Медицинское обозрение. 2018; 2(8–1): 5–11. (Vikulov G.Kh. New and recurring viral infections: Diagnostic and therapeutic algorithms. Russkiy meditsinskiy zhurnal. Meditsinskoye obozreniye = Russian Medical Journal. Medical Review. 2018; 2(8–1): 5–11 (In Russ.)). EDN: YMSNVR.


2. Паевская О.А., Зуевская С.Н., Никифоров В.В. с соавт. Возможности этиотропной терапии в снижении рисков развития тяжелого или осложненного течения ОРВИ и гриппа. РМЖ. 2019; 27(1–2): 77–80. (Paevskaya O.A., Zuevskaya S.N., Nikiforov V.V. et al. Possibilities of etiotropic therapy in reducing the risks of developing severe or complicated acute respiratory viral infections and influenza. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2019; 27(1–2): 77–80 (In Russ.)). EDN: XKNQWF.


3. Duwe S. Influenza viruses – antiviral therapy and resistance. GMS Infect Dis. 2017; 5: Doc04.


https://doi.org/10.3205/id/000030. PMID: 30671326. PMCID: PMC6301739.


4. Денисова А.Р., Максимов М.Л. Острые респираторные вирусные инфекции: этиология, диагностика, современный взгляд на лечение. РМЖ. Медицинское обозрение. 2018; 2(1–2): 99–103. (Denisova A.R., Maksimov M.L. Acute respiratory viral infections: Etiology, diagnosis, modern view of treatment. Russkiy meditsinskiy zhurnal. Meditsinskoye obozreniye = Russian Medical Journal. Medical Review. 2018; 2(1–2): 99–103 (In Russ.)). EDN: XNSLAL.


5. Зырянов С.К., Бутранова О.И., Гайдай Д.С., Крышень К.Л. Фармакотерапия острых респираторных инфекций, вызванных вирусом гриппа. Терапевтический архив. 2021; 93(1): 114–124. (Zyryanov S.K., Butranova O.I., Gaidai D.S., Kryshen K.L. Pharmacotherapy for acute respiratory infections caused by influenza viruses: current possibilities. Terapevticheskiy arkhiv = Therapeutic Archive. 2021; 93(1): 114–124 (In Russ.)).


https://doi.org/10.26442/00403660.2021.01.200551. EDN: UFMUAU.


6. Зайцев А.А. Комбинированные лекарственные средства для симптоматической терапии острых респираторных вирусных инфекций. Практическая пульмонология. 2020; (2): 58–63. (Zaitsev A.A. Combined medicines for symptomatic therapy of acute respiratory viral infections. Prakticheskaya pul’monologiya = Practical Pulmonology. 2020; (2): 58–63 (In Russ.)). EDN: GTKSFD.


7. Пшеничная Н.Ю., Жданов К.В. Предварительные результаты адаптивного рандомизированного открытого контролируемого исследования эффективности и безопасности препарата энисамия йодида для лечения госпитализированных больных с COVID-19. РМЖ. Медицинское обозрение. 2021; 5(11): 705–711. (Pshenichnaya N.Yu., Zhdanov K.V. Preliminary results of an adaptive randomized open-label controlled study on the efficacy and safety of enisamium iodide for outpatient treatment of the COVID-19 infection. Russkiy meditsinskiy zhurnal. Meditsinskoye obozreniye = Russian Medical Journal. Medical Review. 2021; 5(11): 705–711 (In Russ.)).


https://doi.org/10.32364/2587-6821-2021-5-11-705-711. EDN: VBKCBO.


8. Merad V., Martin J.C. Pathological inflammation in patients with COVID-19: A key role monocytes and macrophages. Nat Rev Immunol. 2020; 20(6): 355–62.


https://doi.org/10.1038/s 41577-020-0331-4. PMID: 32376901. PMCID: PMC7201395.


9. Dienz O., Rud J.D., Eaton S.M. et al. Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung. Mucosal Immunol. 2012; 5(3): 258–66.


https://doi.org/10.1038/mi.2012.2. PMID: 22294047. PMCID: PMC3328598.


10. Карева Е.Н., Федотчева Т.А., Семейкин А.В. с соавт. Энисамия йодид – влияние на ключевые компоненты воспалительного процесса. Терапевтический архив. 2022; 94(11): 1262–1267. (Kareva E.N., Fedotcheva T.A., Semeikin A.V. et al. The mechanisms of anti-inflammatory action of enisamium iodide. Terapevticheskiy arkhiv = Therapeutic Archive. 2022; 94(11): 1262–1267 (In Russ.)).


https://doi.org/10.26442/00403660.2022.11.201961. EDN: NOKRCZ.


11. Toots M., Plemper R.K. Next-generation direct-acting influenza therapeutics. Transl Res. 2020; 220: 33–42.


https://doi.org/10.1016/j.trsl.2020.01.005. PMID: 32088166. PMCID: PMC7102518.


12. Hurt A.C. The epidemiology and spread of drug resistant human influenza viruses. Curr Opin Virol. 2014; 8: 22–29.


https://doi.org/10.1016/j.coviro.2014.04.009. PMID: 24866471.


13. Фролов А.Ф., Фролов В.М. Эффективность Амизона в лечении и профилактике вирусных инфекций (к 10-летию применения препарата в клинической практике). Український медичний часопис. 2005; 49(5)-IX/X: 75–80. (Frolov A.F., Frolov V.M. Efficacy of Amizon in the treatment and prevention of viral infections (on the 10th anniversary of the drug’s use in clinical practice). Ukrainskiy medichny chasopis = Ukrainian Medical Periodical. 2005; 49(5)-IX/X: 75–80 (In Russ.)).


14. Крюков Ю.А., Василишин М.С., Сясолятин С.В. с соавт. Опытно-промышленная оценка усовершенствования технологии получения 4-(бензилвабамоил)-1-метилперидиния йодида. Химическая промышленность сегодня. 2020; (3): 48–53. (Kryukov Yu.A., Vasilishin M.S., Sysolyatin S.V. et al. The experience-industrial estimation of the developed reception technology of n-metil-4-benzilkarbamidopiridiniya iodide. Khimicheskaya promyshlennost’ segodnya = Chemical Industry Developments. 2020; (3): 48–53 (In Russ.)). EDN: IZMXGY.


15. Крюков Ю.А., Рогова А.И., Сысолятин С.В. Разработка получения N-метил-4-бензилкарбамидо-пиридиния йодида. Ползуновский вестник. 2013; (3): 119–124. (Kryukov Yu.A., Rogova A.I., Sysolyatin S.V. Development of the production of N-methyl-4-benzylurea-pyridinium iodide. Polzunovskiy vеstnik = Polzunov Bulletin. 2013; (3): 119–124 (In Russ.)). EDN: RDDXFX.


16. Boltz D., Peng X., Muzzio M. et al. Activity of enisamium, an isonicotinic acid derivative, against influenza viruses in differentiated normal human bronchial epithelial cells. Antivir Chem Chemother. 2018; 26: 2040206618811416.


https://doi.org/10.1117/2040206618811416. PMID: 30466301. PMCID: PMC6961345.


17. Walker A.P., Fan H., Keown J.R. et al. Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases. bioRxiv. 2020: 2020.04.21.053017.


https://doi.org/10.1101/2020.04.21.053017. PMID: 32511388. PMCID: PMC7263517.


18. Фролов А.Ф., Фролов В.М., Бухтиарова Т.А., Даниленко В.Ф. Клинические аспекты применения Амизона. Украинский медицинский журнал. 2004; 39(1): 69–74. (Frolov A.F., Frolov V.M., Bukhtiarova T.A., Danilenko V.F. Clinical aspects of the use of Amizon. Ukrainskiy meditsinskiy zhurnal = Ukrainian Medical Journal. 2004; 39(1): 69–74 (In Russ.)).


19. Пшеничная Н.Ю., Булгакова В.А., Волчкова Е.В. Обзор текущих и перспективных направлений противовирусной терапии гриппа и острых респираторных вирусных инфекций в России. Терапевтический архив. 2019; 91(11): 105–109. (Pshenichnaya N.Yu., Bulgakova V.A., Volchkova E.V. et al. Review of current and future directions of antiviral therapy of influenza and acute respiratory viral infections in Russia. Terapevticheskiy arkhiv = Therapeutic Archive. 2019; 91(11): 105–109 (In Russ.)).


https://doi.org/10.26442/00403660.2019.11.000454. EDN: LMGOIN.


20. Zhulai T.S. The preclinical study of a new nasal spray with the anti-inflammatory properties: the effect on the leukotriene-induced inflammation. Clinical Pharmacy. 2018; 22(4): 27–33.


https://doi.org/10.24959/cphj.18.1473.


21. Лиознов Д.А., Карнаухова Е.Ю., Зубкова Т.Г., Шахланская Е.В. Оценка эффективности схемы лечения ОРВИ, включающей этиотропную (энисамия йодид) и симптоматическую терапию. Терапевтический архив. 2020; 92(3): 50–55. (Lioznov D.A., Karnaukhova E.Yu., Zubkova T.G., Shakhlanskaya E.V. Evaluation of the effectiveness of ARVI treatment regimen including etiotropic (enisamium iodide) and symptomatic treatment. Terapevticheskiy arkhiv = Therapeutic Archive. 2020; 92(3): 50–55 (In Russ.)).


https://doi.org/10.26442/00403660.2020.03.000572. EDN: NXCEXE.


22. Zhai P., Ding Y., Wu X. et al. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agets. 2020; 55(5): 105955.


https://doi.org/10.1016/j.ijantimicag.2020.105955. PMID: 32234468. PMCID: PMC7138178.


23. Мельникова Т.И., Деева Э.Г., Амосова И.В. с соавт. Клиническая эффективность Амизона в терапии гриппа и других острых респираторных вирусных инфекций. Здоровья Украіни. 2013; (17): 40–41. (Melnikova T.I., Deeva E.G., Amosova I.V. et al. Clinical effectiveness of Amizon in the treatment of influenza and other acute respiratory viral infections. Zdorov’ye Ukrainy = Health of Ukraine. 2013; (17): 40–41 (In Russ.)).


24. Зарубаев В.В., Слита А.В., Синегубова Е.О. с соавт. Противовирусная активность энисамия йодида в отношении вирусов гриппа и ОРВИ in vitro на различных клеточных линиях. Терапевтический архив. 2020; 92(11): 45–50. (Zarubaev V.V., Slita A.V., Sinegubova E.O. et al. Anti-viral activity of enisamium iodide against viruses of influenza and ARVI’s on different cell lines. Terapevticheskiy arkhiv = Therapeutic Archive. 2020; 92(11): 45–50 (In Russ.)).


https://doi.org/10.26442/00403660.2020.11.000872. EDN: PTSPNQ.


About the Autors

Olga V. Cherenkova, MD, PhD (Medicine), associate professor of the Department of clinical pharmacology, N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia. Address: 394036, Voronezh, 10 Studencheskaya St.
E-mail: cherenkova.o.v@yandex.ru
ORCID: https://orcid.org/0000-0001-5320-2720
Natalia Yu. Goncharova, MD, PhD (Medicine), associate professor of the Department of clinical pharmacology, N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia. Address: 394036, Voronezh, 10 Studencheskaya St.
E-mail: _sumerki_@mail.ru
ORCID: https://orcid.org/0000-0002-4113-5206
Galina A. Batishcheva, MD, Dr. Sci. (Medicine), professor of the Department of clinical pharmacology, N.N.Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia. Address: 394036, Voronezh, 10 Studencheskaya St.
E-mail: bat13@mail.ru
ORCID: https://orcid.org/0000-0003-4771-7466


Similar Articles

Back to Content

Бионика Медиа